Consumer Reports takes aim at medical device industry; County takes aim at Pfizer tax breaks;

> The influential Consumer Reports, which reviews consumer products, is taking aim at the FDA's fast-track process for the approval of medical devices, saying some of them could be a "ticking time bomb." Story

> Lee County, NC, commissioners are considering revoking hundreds of thousands of dollars worth of tax incentives for Pfizer ($PFE). The pharmaceutical company is scaling back at its Sanford, NC, plant, so the commissioners may demand a refund of rebates the drugmaker has already received. News

> Ranbaxy Laboratories ($RANBXY.NS), has started operations at a new facility in Morocco, its third in Africa. Story

> Drugmaker Mylan ($MYL) expects to complete by next year a 280,000-square-foot, LEED-certified headquarters facility near its current location in Washington County, PA. Mylan release

> Japan's Asahi Kasei will buy Zoll Medical ($ZOLL), the Chelmsford, MA, maker of software--as well as resuscitation and critical care devices--for $2.21 billion. News

> DSM Pharmaceutical Products, which has been manufacturing the cancer therapy talactoferrin for Agennix for use in clinical trials, has an agreement to produce the med at commercial levels upon its potential approval. Item

> U.K.-based SCM Pharma, a contract development and manufacturing organization that specializes in sterile manufacturing, has invested £500,000 in new vial filling equipment to meet the needs of a new order. Release

Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.